Aclaris Therapeutis (ACRS) PT Lowered to $34 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures edge lower after AI selloff, telecom slide
- Meta’s capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on concern over Middle East escalation
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Price: $3.83 --0%
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 9 | New: 15
Rating Summary:
15 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 9 | New: 15
Join SI Premium – FREE
JMP Securities analyst Donald Ellis lowered the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $34.00 (from $47.00) while maintaining a Market Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SAP (SAP:GR) (SAP) PT Raised to EUR240 at HSBC
- Samsung E&A (028050:KS) PT Raised to KRW66,000 at Macquarie
- Bursa Malaysia Bhd (BURSA:MK) PT Lowered to MYR9.40 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
